Catalyst Pharmaceuticals (CPRX) EBIAT (2010 - 2026)
Catalyst Pharmaceuticals posted quarterly EBIAT of $63.7 million for Q1 2026, up 12.33% year-on-year from $56.7 million in Q1 2025, and up 20.94% on a QoQ basis from $52.7 million in Q4 2025.
Catalyst Pharmaceuticals (CPRX) has 17 years of EBIAT data on file, last reported at $63.7 million in Q1 2026.
- For the quarter ending Q1 2026, EBIAT rose 12.33% year-over-year to $63.7 million; the trailing twelve-month figure through Mar 2026 stood at $221.3 million (up 12.15% YoY), and the FY2025 full-year result was $214.3 million, up 30.78% from the prior year.
- EBIAT for Q1 2026 stood at $63.7 million, up from $52.7 million in the prior quarter.
- Across five years, EBIAT topped out at $63.7 million in Q1 2026 and bottomed at -$30.8 million in Q3 2023.
- The 5-year median for EBIAT is $37.8 million (2023), against an average of $35.1 million.
- The widest annual swing landed in 2023, when EBIAT slumped 235.24%; it then soared 242.65% in 2024.
- A 5-year view of EBIAT shows it stood at $25.5 million in 2022, then jumped by 36.8% to $34.8 million in 2023, then surged by 60.53% to $55.9 million in 2024, then retreated by 5.79% to $52.7 million in 2025, then rose by 20.94% to $63.7 million in 2026.
- The last three EBIAT figures came in at $63.7 million (Q1 2026), $52.7 million (Q4 2025), and $52.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 30.90 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.63 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Catalyst Pharmaceuticals | 3.82 Bn | 3.07 Bn | 134.92 Mn | 63.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 63.73 Mn |
| Dec 31, 2025 | 52.70 Mn |
| Sep 30, 2025 | 52.78 Mn |
| Jun 30, 2025 | 52.11 Mn |
| Mar 31, 2025 | 56.74 Mn |
| Dec 31, 2024 | 55.94 Mn |
| Sep 30, 2024 | 43.88 Mn |
| Jun 30, 2024 | 40.79 Mn |
| Mar 31, 2024 | 23.28 Mn |
| Dec 31, 2023 | 34.84 Mn |
| Sep 30, 2023 | -30.76 Mn |
| Jun 30, 2023 | 37.76 Mn |
| Mar 31, 2023 | 29.57 Mn |
| Dec 31, 2022 | 25.47 Mn |
| Sep 30, 2022 | 22.75 Mn |
| Jun 30, 2022 | 21.62 Mn |
| Mar 31, 2022 | 13.24 Mn |
| Dec 31, 2021 | 9.31 Mn |
| Sep 30, 2021 | 10.33 Mn |
| Jun 30, 2021 | 12.18 Mn |
| Mar 31, 2021 | 7.66 Mn |
| Dec 31, 2020 | 11.44 Mn |
| Sep 30, 2020 | 43.34 Mn |
| Jun 30, 2020 | 9.78 Mn |
| Mar 31, 2020 | 10.43 Mn |
| Dec 31, 2019 | 7.93 Mn |
| Sep 30, 2019 | 13.63 Mn |
| Jun 30, 2019 | 10.96 Mn |
| Mar 31, 2019 | -644,503.00 |
| Dec 31, 2018 | -14.50 Mn |
| Sep 30, 2018 | -7.84 Mn |
| Jun 30, 2018 | -5.97 Mn |
| Mar 31, 2018 | -5.70 Mn |
| Dec 31, 2017 | -5.39 Mn |
| Sep 30, 2017 | -4.18 Mn |
| Jun 30, 2017 | -3.88 Mn |
| Mar 31, 2017 | -4.97 Mn |
| Dec 31, 2016 | -4.16 Mn |
| Sep 30, 2016 | -3.95 Mn |
| Jun 30, 2016 | -4.57 Mn |
| Mar 31, 2016 | -5.39 Mn |
| Dec 31, 2015 | -5.82 Mn |
| Sep 30, 2015 | -4.45 Mn |
| Jun 30, 2015 | -4.56 Mn |
| Mar 31, 2015 | -5.41 Mn |
| Dec 31, 2014 | -3.49 Mn |
| Sep 30, 2014 | -5.01 Mn |
| Jun 30, 2014 | -3.20 Mn |
| Mar 31, 2014 | -3.81 Mn |
| Dec 31, 2013 | -1.35 Mn |
| Sep 30, 2013 | -5.91 Mn |
| Jun 30, 2013 | -3.14 Mn |
| Mar 31, 2013 | -1.74 Mn |
| Dec 31, 2012 | -76,585.00 |
| Sep 30, 2012 | -2.62 Mn |
| Jun 30, 2012 | -289,080.00 |
| Mar 31, 2012 | -1.09 Mn |
| Dec 31, 2011 | -2.35 Mn |
| Sep 30, 2011 | -1.13 Mn |
| Jun 30, 2011 | -1.39 Mn |
| Mar 31, 2011 | -1.52 Mn |
| Dec 31, 2010 | -728,754.00 |
| Sep 30, 2010 | -903,985.00 |